Mirati Therapeutics Inc. (NASDAQ:MRTX) – Leerink Swann issued their FY2018 EPS estimates for Mirati Therapeutics in a report issued on Thursday. Leerink Swann analyst M. Schmidt expects that the brokerage will post earnings of ($3.66) per share for the year. Leerink Swann currently has a “Hold” rating and a $7.00 price target on the stock.

Earnings History and Estimates for Mirati Therapeutics (NASDAQ:MRTX)

A number of other brokerages also recently issued reports on MRTX. Wedbush restated an “outperform” rating and issued a $12.00 price target on shares of Mirati Therapeutics in a research report on Tuesday, October 4th. Zacks Investment Research upgraded Mirati Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 6th. Finally, Piper Jaffray Cos. restated a “neutral” rating on shares of Mirati Therapeutics in a research report on Friday, August 19th. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Mirati Therapeutics has a consensus rating of “Buy” and an average price target of $16.72.

Mirati Therapeutics (NASDAQ:MRTX) opened at 5.60 on Monday. The stock’s market capitalization is $111.57 million. Mirati Therapeutics has a 12 month low of $4.40 and a 12 month high of $42.70. The firm’s 50-day moving average is $5.56 and its 200-day moving average is $8.06.

Several institutional investors have recently made changes to their positions in the stock. KCG Holdings Inc. purchased a new position in shares of Mirati Therapeutics during the second quarter valued at approximately $102,000. Citadel Advisors LLC raised its position in shares of Mirati Therapeutics by 72.3% in the second quarter. Citadel Advisors LLC now owns 22,064 shares of the company’s stock valued at $120,000 after buying an additional 9,258 shares in the last quarter. Alliancebernstein L.P. purchased a new position in shares of Mirati Therapeutics during the second quarter valued at approximately $125,000. Tower Research Capital LLC TRC raised its position in shares of Mirati Therapeutics by 189.8% in the third quarter. Tower Research Capital LLC TRC now owns 20,214 shares of the company’s stock valued at $134,000 after buying an additional 13,240 shares in the last quarter. Finally, California State Teachers Retirement System raised its position in shares of Mirati Therapeutics by 9.5% in the second quarter. California State Teachers Retirement System now owns 26,594 shares of the company’s stock valued at $145,000 after buying an additional 2,300 shares in the last quarter. Hedge funds and other institutional investors own 69.49% of the company’s stock.

5 Day Chart for NASDAQ:MRTX

Receive News & Stock Ratings for Mirati Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics Inc. and related stocks with our FREE daily email newsletter.